Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
Public ClinicalTrials.gov record NCT00846989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 4-week Multi-center, Single-masked, Randomized, Latanoprost-controlled, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of RKI983 (0.05% and 0.10%) Ophthalmic Solution Given Twice a Day Versus Once Daily Latanoprost 0.005%, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
Study identification
- NCT ID
- NCT00846989
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 276 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2009 (Type not available)
- Primary completion
- Apr 2009 (Actual)
- Completion
- Apr 2009 (Actual)
- Last update posted
- Dec 19, 2020
2009
United States locations
- U.S. sites
- 29
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Artesia | California | 90701 | — |
| Novartis Investigative Site | Inglewood | California | 90301 | — |
| Novartis Investigative Site | La Jolla | California | 92037 | — |
| Novartis Investigative Site | Poway | California | 92064 | — |
| Novartis Investigative Site | Stockton | California | 95207 | — |
| Novartis Investigative Site | Danbury | Connecticut | 06810 | — |
| Novartis Investigative Site | Atlanta | Georgia | 30342 | — |
| Novartis Investigative Site | Morrow | Georgia | 30260 | — |
| Novartis Investigative Site | Roswell | Georgia | 30076 | — |
| Novartis Investigative Site | Kaneohe | Hawaii | 96744 | — |
| Novartis Investigative Site | Topeka | Kansas | 66606 | — |
| Novartis Investigative Site | Louisville | Kentucky | 40217 | — |
| Novartis Investigative Site | Bossier City | Louisiana | 71111 | — |
| Novartis Investigative Site | Cambridge | Massachusetts | 02142 | — |
| Novartis Investigative Site | Springfield | Missouri | 65804 | — |
| Novartis Investigative Site | Omaha | Nebraska | 68131 | — |
| Novartis Investigative Site | Las Vegas | Nevada | 89148 | — |
| Novartis Investigative Site | Bethpage | New York | 11714 | — |
| Novartis Investigative Site | Lynbrook | New York | 11563 | — |
| Novartis Investigative Site | Rochester | New York | 14618 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28204 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28210 | — |
| Novartis Investigative Site | Tulsa | Oklahoma | 74104 | — |
| Novartis Investigative Site | Mt. Pleasant | South Carolina | 29464 | — |
| Novartis Investigative Site | Memphis | Tennessee | 38119 | — |
| Novartis Investigative Site | El Paso | Texas | 79904 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | San Antonio | Texas | 78229 | — |
| Novartis Investigative Site | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00846989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 19, 2020 · Synced Nov 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00846989 live on ClinicalTrials.gov.